Expected impact nr.1 – according to the call text
Actions will lead to the creation of new (or significant upgrades of existing) Centres of Excellence in Member States and regions currently identified as low performers in terms of research and innovation, increasing on the one hand their scientific capabilities and on the other, enabling them to engage in a strategic growth path in terms of economic development.
It is also expected that improved scientific capabilities will allow them to improve their chances to seek competitive funding in international fora (including the EU Framework Programmes).
Activities done to reach this expected impact:
Exchange of best practices have been analyzed
1. Cooperation with EMBL who was a member of the consortium by undertaking several visits (eg. infrastructural planning, SC meeting) and
2. Cooperation with the members of the International Advisory Board (IAB) who were visited by the Scientific Director of the project and by some SC member. The IAB consisted of the
- VIB which is a life sciences research institute in Flanders, Belgium which performs basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications. As VIB works in close partnership with four five universities − UGent, KU Leuven, University of Antwerp, Vrije University Brussel and Hasselt University and is funded by the Flemish government, VIB has provided a number of good examples of working methods and approaches to the different WPs of HU-MOLMEDEX. VIB was represented by Mr. Jo Bury.
- FIMM is a similar institute in Finland and has offered a series of good practices for HU-Molmedex. The Institute for Molecular Medicine Finland (FIMM) is an international research institute in Helsinki focusing on human genomics and personalized medicine. FIMM integrates molecular medicine research, Technology Centre and Biobanking Infrastructures “under one roof” and thereby promotes translational research and adoption of personalized medicine in health care. FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centers for molecular medicine in Norway, Sweden and Denmark. At the national level, FIMM is a joint research institute of the University of Helsinki (primary host), the Hospital District of Helsinki and Uusimaa, the National Institute for Health and Welfare, and VTT Technical Research Centre of Finland. FIMM was represented by Mr. Olli Kallioniemi.
3. Two high level scientists representing two good practice institute have accepted the participation in the International Advisory Board, namely Mr. Bass Hassan at University of Oxford and Luis Serrano at CRG Barcelona, who contributed actively to the Business Plan development process as IAB members.
As VIB and CRG are founding members of the EU_Life, the HU_Molmedex consortium decided to join this programme after setting up HCEMM.
Expected impact nr. 2 – according to call
Over the medium to long term there will be a measurable and significant improvement in the research and innovation culture (such as research intensity, innovation performance, enhanced strategy, values and attitudes towards research and innovation) within Member States currently with low R&I performance.
These will be fostered through constructive and sustainable partnerships achieved between research and innovation-intensive institutions of excellence and the partnering organisation in the low performing Member State or region.
Activities done to reach this expected impact
As culture is based on the people and the processes governing the life of an organization, a cultural change may be induced by the exchange of researchers, inclusion of new processes, mechanisms to support competitive research in the field of molecular medicine. It has been agreed and included into the Business Plan that the main goal of creating the new center of excellence is to develop an autonomous, “game changer” organization, which can influence the research environment in a large segment of the Hungarian institutional and university environment with a long term reforming effect.
The internal processes of the one year action were orchestrated in a way to allow the free exchange of ideas within the consortium and with and from the organizations as listed in chapter 1.3 a)
Target groups for the communications are defined as the public, researchers’ community, decision makers, business developers and industry during creating the technical and professional guidelines of the communication strategy.
As a Center of Excellence, HCEMM will communicate the groundbreaking science and its innovative research programs with and to the public. This is achieved through several initiatives to the wide range of audiences: from students and citizens, to journalists and politicians.
As HCEMM is expected to take the lead in creating a scientific community in the different regions, in which communication and networking is a constant feature, fast and efficient information channels were defined in the Business Plan.
Expected impact nr.3 – according to call
Benefits will also accrue to the institutions from the more intensive research and innovation performers, in terms of issues such as access to new research avenues, creativity and the development of new approaches, as well as a source for increased mobility (inwards and outwards) of qualified scientists
Activities done to reach this expected impact
The communication to the wider scientific community will be based on the partnership with the EMBL which was analysed quite deeply during the project. During the HU-Molmedex project implementation the preparatory work was done to become a fully assessed member state and to be part of the EMBL partnership. Therefore HCEMM will be embedded into the scientific community at the European level and worldwide. The key component of this will be related to the shared use of the EMBL logo. The communication to the wider scientific community will be based on the partnership with the EMBL. By becoming a full member state and being part of the EMBL partnership HCEMM will be embedded into the scientific community at the European level and worldwide. The key component of this partnership will be related to the shared use of the EMBL logo which will contribute to better integration and participation of HCEMM research groups. HCEMM will be able to refer to the partnership with the EMBL in its promotional material, including job offers, which is expected to attract well qualified young researchers.